Piper Sandler Appoints Two Managing Directors to Lead New Group
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy PIPR?
Piper Sandler Companies announced the additions of John Mori and Eric Friel as managing directors to lead a new group that will focus on distressed debt and special assets. Mori will be based in Greenwich and Friel will be in New York, both reporting to Michael Piper, head of fixed income at Piper Sandler. The distressed debt and special asset group will source and trade specialized credit products, including distressed assets, trade and insurance claims, reorganized equity and other securities issued by companies facing financial stress, including default or bankruptcy. Additional new hires will be announced in the coming weeks and months. The group will also work in partnership with the firm's investment banking, capital markets and restructuring teams.Mori and Friel join the firm from Oppenheimer & Co., where Mori was co-head of distressed debt and Friel was head of high-yield and distressed research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PIPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PIPR
Wall Street analysts forecast PIPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 80.550
Low
386.00
Averages
386.00
High
386.00
Current: 80.550
Low
386.00
Averages
386.00
High
386.00
About PIPR
Piper Sandler Companies is an investment bank and institutional securities firm, serving corporations, private equity groups, public entities, non-profit entities, and institutional investors in the United States and internationally. The Company provides products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It offers equity and fixed income advisory and trade execution services for institutional investors, corporations, and government and non-profit entities. Its segment provides investment banking services, institutional sales and trading services for various equity and fixed income products, and research services. It operates alternative asset management funds in merchant banking and healthcare to invest firm capital and manage capital from outside investors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CF Bankshares Named Among 12 Best Micro-Cap Dividend Stocks to Buy Now
- Earnings Warning: Piper Sandler analyst Adam Kroll lowered the price target for CF Bankshares from $34 to $33.50 while maintaining an Overweight rating; however, a $0.5 million interest reversal due to an increase in non-performing loans impacted PPNR and EPS, indicating pressure on the company's profitability.
- Financial Performance: CF Bankshares reported mixed results in its latest earnings report, with an increase in non-core loans leading to a shortfall in earnings, although the company's turnaround since its 2012 recapitalization has been deemed 'impressive', short-term profitability remains a concern.
- Market Competitiveness: Piper Sandler highlighted that CF Bankshares has a stronger-than-peer organic balance sheet growth outlook, with expectations for modest net interest margin expansion that could support further profitability improvements, despite competitive pressures in the market.
- Investment Potential: While CF Bankshares shows investment potential, analysts believe that certain AI stocks offer greater upside potential and carry less downside risk, prompting investors to carefully consider market dynamics when making investment decisions.
See More
CRISPR Therapeutics Shows Promising Upside Potential
- Strong Stock Performance: CRISPR Therapeutics' shares have surged 56% over the past year, significantly outperforming the S&P 500's 30% gain, indicating robust market confidence in its growth prospects.
- Optimistic Analyst Targets: According to Yahoo! Finance, CRISPR's average price target is $82.55, suggesting nearly 51% upside from current levels, while Piper Sandler's analyst has set a target of $110, indicating the stock could potentially double in the next 12 months.
- Catalysts from Clinical Trials: The ongoing development of the anticoagulant CTX611 could yield crucial clinical trial data in the coming months, targeting a $20 billion market, and positive results could significantly boost the stock price.
- Market Expansion Potential: The Casgevy drug, developed in collaboration with Vertex Pharmaceuticals, has yet to generate significant sales despite its 2023 approval due to its complex administration and high cost; however, the recent request for approval for children aged 5 to 11 could greatly expand its market potential, with annual revenues expected to exceed $1 billion in the coming years.
See More
Trump Tariff Refunds Could Benefit Nike Significantly
- Tariff Refund Potential: Analysts estimate that Nike could significantly benefit from Trump tariff refunds, with expected boosts of 36% to earnings per share (EPS) and earnings before interest and taxes (EBIT), providing crucial financial support as its stock has declined over 30% this year.
- Capital Allocation Strategy: Analysts indicate that Nike plans to use the refunds for debt reduction, share buybacks, and investment spending without lowering consumer prices, demonstrating a robust capital management strategy amid market pressures.
- Legal Challenges Impact: Despite a class action lawsuit filed by consumers against Nike, arguing that the company should not retain tariff refunds passed on to consumers through higher prices, analysts still view the refunds as a positive catalyst expected to arrive in July and August.
- Market Reaction and Confidence: Nike's stock plunged 15% after a disappointing earnings report in March and is now down about 45% from its 52-week high, yet the recent $1 million stock purchases by its CEO and Apple’s CEO indicate strong management confidence in the company's future.
See More
Piper Sandler Forms New Distressed Debt Team Led by Industry Veterans
- New Team Formation: Piper Sandler Companies announces the appointment of John Mori and Eric Friel as managing directors to lead a newly formed distressed debt and special assets group, focusing on trading specialized credit products such as distressed assets and insurance claims.
- Market Opportunity Capture: This team will collaborate with the firm's investment banking, capital markets, and restructuring teams to leverage current market volatility and regulatory changes, helping investors navigate challenges in the distressed market and enhancing the firm's competitive position.
- Rich Industry Experience: Mori and Friel join from Oppenheimer & Co., where Mori was co-head of distressed debt and Friel led high-yield and distressed research, bringing valuable industry backgrounds that will provide Piper Sandler with unique investment opportunities.
- Strategic Value Enhancement: Michael Piper stated that this expansion will offer clients access to unique investment opportunities previously unaddressed, further strengthening Piper Sandler's service capabilities in the distressed debt space and is expected to create significant value for institutional clients.
See More
Piper Sandler (PIPR.US) Officer Plans to Sell $3.62 Million in Common Stock via Form 144
Stock Sale Announcement: Jonathan Doyle plans to sell 45,000 shares of Piper Sandler's common stock on May 5, with an estimated market value of approximately $3.62 million.
Reduction in Shareholding: Since May 4, 2026, Jonathan Doyle has reduced his shareholding in Piper Sandler by 45,000 shares, valued at around $3.47 million.
See More
AI COULD PLAY A CRUCIAL ROLE IN INCREASING RETURNS FOR THE WEALTH DIVISION - CEO JANE FRASER
CEO Announcement: Jane Fraser has been appointed as the CEO of Citigroup, marking a significant leadership change in the financial sector.
Focus on Wealth Division: Under her leadership, there is an emphasis on enhancing the wealth division, aiming to improve returns and client services.
See More
CF Bankshares Named Among 12 Best Micro-Cap Dividend Stocks to Buy Now
- Earnings Warning: Piper Sandler analyst Adam Kroll lowered the price target for CF Bankshares from $34 to $33.50 while maintaining an Overweight rating; however, a $0.5 million interest reversal due to an increase in non-performing loans impacted PPNR and EPS, indicating pressure on the company's profitability.
- Financial Performance: CF Bankshares reported mixed results in its latest earnings report, with an increase in non-core loans leading to a shortfall in earnings, although the company's turnaround since its 2012 recapitalization has been deemed 'impressive', short-term profitability remains a concern.
- Market Competitiveness: Piper Sandler highlighted that CF Bankshares has a stronger-than-peer organic balance sheet growth outlook, with expectations for modest net interest margin expansion that could support further profitability improvements, despite competitive pressures in the market.
- Investment Potential: While CF Bankshares shows investment potential, analysts believe that certain AI stocks offer greater upside potential and carry less downside risk, prompting investors to carefully consider market dynamics when making investment decisions.
See More
CRISPR Therapeutics Shows Promising Upside Potential
- Strong Stock Performance: CRISPR Therapeutics' shares have surged 56% over the past year, significantly outperforming the S&P 500's 30% gain, indicating robust market confidence in its growth prospects.
- Optimistic Analyst Targets: According to Yahoo! Finance, CRISPR's average price target is $82.55, suggesting nearly 51% upside from current levels, while Piper Sandler's analyst has set a target of $110, indicating the stock could potentially double in the next 12 months.
- Catalysts from Clinical Trials: The ongoing development of the anticoagulant CTX611 could yield crucial clinical trial data in the coming months, targeting a $20 billion market, and positive results could significantly boost the stock price.
- Market Expansion Potential: The Casgevy drug, developed in collaboration with Vertex Pharmaceuticals, has yet to generate significant sales despite its 2023 approval due to its complex administration and high cost; however, the recent request for approval for children aged 5 to 11 could greatly expand its market potential, with annual revenues expected to exceed $1 billion in the coming years.
See More
Trump Tariff Refunds Could Benefit Nike Significantly
- Tariff Refund Potential: Analysts estimate that Nike could significantly benefit from Trump tariff refunds, with expected boosts of 36% to earnings per share (EPS) and earnings before interest and taxes (EBIT), providing crucial financial support as its stock has declined over 30% this year.
- Capital Allocation Strategy: Analysts indicate that Nike plans to use the refunds for debt reduction, share buybacks, and investment spending without lowering consumer prices, demonstrating a robust capital management strategy amid market pressures.
- Legal Challenges Impact: Despite a class action lawsuit filed by consumers against Nike, arguing that the company should not retain tariff refunds passed on to consumers through higher prices, analysts still view the refunds as a positive catalyst expected to arrive in July and August.
- Market Reaction and Confidence: Nike's stock plunged 15% after a disappointing earnings report in March and is now down about 45% from its 52-week high, yet the recent $1 million stock purchases by its CEO and Apple’s CEO indicate strong management confidence in the company's future.
See More
Piper Sandler Forms New Distressed Debt Team Led by Industry Veterans
- New Team Formation: Piper Sandler Companies announces the appointment of John Mori and Eric Friel as managing directors to lead a newly formed distressed debt and special assets group, focusing on trading specialized credit products such as distressed assets and insurance claims.
- Market Opportunity Capture: This team will collaborate with the firm's investment banking, capital markets, and restructuring teams to leverage current market volatility and regulatory changes, helping investors navigate challenges in the distressed market and enhancing the firm's competitive position.
- Rich Industry Experience: Mori and Friel join from Oppenheimer & Co., where Mori was co-head of distressed debt and Friel led high-yield and distressed research, bringing valuable industry backgrounds that will provide Piper Sandler with unique investment opportunities.
- Strategic Value Enhancement: Michael Piper stated that this expansion will offer clients access to unique investment opportunities previously unaddressed, further strengthening Piper Sandler's service capabilities in the distressed debt space and is expected to create significant value for institutional clients.
See More
Piper Sandler (PIPR.US) Officer Plans to Sell $3.62 Million in Common Stock via Form 144
Stock Sale Announcement: Jonathan Doyle plans to sell 45,000 shares of Piper Sandler's common stock on May 5, with an estimated market value of approximately $3.62 million.
Reduction in Shareholding: Since May 4, 2026, Jonathan Doyle has reduced his shareholding in Piper Sandler by 45,000 shares, valued at around $3.47 million.
See More
AI COULD PLAY A CRUCIAL ROLE IN INCREASING RETURNS FOR THE WEALTH DIVISION - CEO JANE FRASER
CEO Announcement: Jane Fraser has been appointed as the CEO of Citigroup, marking a significant leadership change in the financial sector.
Focus on Wealth Division: Under her leadership, there is an emphasis on enhancing the wealth division, aiming to improve returns and client services.
See More
